A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children With Recurrent or Refractory Solid Tumors
Study for children with recurrent or refractory solid tumors using study drug axitinib
Sponsor: Children's Oncology Group
Enrolling: Male and Female Patients
IRB Number: AAAO2953
U.S. Govt. ID: NCT02164838
Contact: Catherine Poulcallec-Gordon: 212-305-2478 / cnp2105@columbia.edu
Additional Study Information: The purpose of this study is to assess the safety and effectiveness of a study drug called axitinib on treating tumors that have returned (recurrent) or have not responded to standard therapy (refractory). Children will take axitinib twice a day for 28 days (1 cycle). Children may take study drug for up to 24 cycles (2 years).
This study is closed
Investigator
Julia Glade Bender, MD
Do You Qualify?
Does your child have refractory or recurrent solid tumors (not CNS)? Yes No
Are you currently receiving any investigational drugs or anti-cancer agents? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Catherine Poulcallec-Gordon
cnp2105@columbia.edu
212-305-2478
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE